Literature DB >> 26450625

Upregulation of mitogen-inducible gene 6 triggers antitumor effect and attenuates progesterone resistance in endometrial carcinoma cells.

W Xu1, S Zhu1, Y Zhou1, Y Jin1, H Dai1, X Wang1.   

Abstract

Researches regarding mitogen-inducible gene 6 (Mig-6) have confirmed its role as a tumor suppressor and progesterone resistance factor in endometrium. In this study, after confirming the downregulation of Mig-6 protein in endometrial carcinoma (EC) tissues, the expression of Mig-6 was upregulated in Ishikawa cells by pCMV6-Mig-6 plasmid. We observed the increased apoptosis, decreased proliferation and invasion potential of Ishikawa cells after upregulation of Mig-6. The proapoptosis ability of P4 significantly enhanced by 39.36%, the antiproliferation ability increased by 37.90% and the anti-invasion ability increased by 48.89%, suggesting the antiprogesterone resistance potential of Mig-6 in endometrium. In addition, the results suggested that Mig-6 may induce Ishikawa cell apoptosis through the mitochondrial pathway, inhibit cell proliferation via the extracellular signal-regulated kinase pathway and the anti-invasion potential may associate with matrix metalloproteinase (MMP)-2 and MMP-9 downexpression. Therefore, upregulation of Mig-6 may add a new strategy to suppress endometrial tumorigenesis and attenuate the progesterone resistance during P4 treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26450625     DOI: 10.1038/cgt.2015.52

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  43 in total

1.  Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis.

Authors:  Richard O Burney; Said Talbi; Amy E Hamilton; Kim Chi Vo; Mette Nyegaard; Camran R Nezhat; Bruce A Lessey; Linda C Giudice
Journal:  Endocrinology       Date:  2007-05-17       Impact factor: 4.736

2.  Mig-6 is a negative regulator of the epidermal growth factor receptor signal.

Authors:  P O Hackel; M Gishizky; A Ullrich
Journal:  Biol Chem       Date:  2001-12       Impact factor: 3.915

3.  Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma.

Authors:  Tomoyuki Miyamoto; Jun Watanabe; Hiroki Hata; Toshiko Jobo; Miwa Kawaguchi; Manabu Hattori; Mayumi Saito; Hiroyuki Kuramoto
Journal:  J Steroid Biochem Mol Biol       Date:  2004-10       Impact factor: 4.292

4.  Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers.

Authors:  S Nomoto; N Haruki; Y Tatematsu; H Konishi; T Mitsudomi; T Takahashi; T Takahashi
Journal:  Genes Chromosomes Cancer       Date:  2000-07       Impact factor: 5.006

Review 5.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

Review 6.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Authors:  Dennis W Stacey
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

7.  Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.

Authors:  Daniel T Ruan; Robert S Warren; Jacob Moalem; Ki-Wook Chung; Ann C Griffin; Wen Shen; Quan-Yang Duh; Eric Nakakura; David B Donner; Elham Khanafshar; Julie Weng; Orlo H Clark; Electron Kebebew
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

Review 8.  Feedback inhibitors of the epidermal growth factor receptor signaling pathways.

Authors:  Noriko Gotoh
Journal:  Int J Biochem Cell Biol       Date:  2008-08-09       Impact factor: 5.085

9.  Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer.

Authors:  Tae Hoon Kim; Dong-Kee Lee; Sung-Nam Cho; Grant D Orvis; Richard R Behringer; John P Lydon; Bon Jeong Ku; Adrienne S McCampbell; Russell R Broaddus; Jae-Wook Jeong
Journal:  Cancer Res       Date:  2013-06-27       Impact factor: 12.701

10.  Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.

Authors:  Z Xia; M Dickens; J Raingeaud; R J Davis; M E Greenberg
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

View more
  4 in total

1.  Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.

Authors:  Hirofumi Ando; Tsutomu Miyamoto; Hiroyasu Kashima; Shotaro Higuchi; Koichi Ida; David Hamisi Mvunta; Tanri Shiozawa
Journal:  Horm Cancer       Date:  2017-05-17       Impact factor: 3.869

2.  Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases.

Authors:  Kendall J Keck; Patrick Breheny; Terry A Braun; Benjamin Darbro; Guiying Li; Joseph S Dillon; Andrew M Bellizzi; Thomas M O'Dorisio; James R Howe
Journal:  Surgery       Date:  2017-11-16       Impact factor: 3.982

3.  Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.

Authors:  Xiaohong Ma; Tianyi Zhao; Hong Yan; Kui Guo; Zhiming Liu; Lina Wei; Wei Lu; Chunping Qiu; Jie Jiang
Journal:  Cell Death Dis       Date:  2021-05-26       Impact factor: 8.469

Review 4.  Gene 33/Mig6/ERRFI1, an Adapter Protein with Complex Functions in Cell Biology and Human Diseases.

Authors:  Dazhong Xu; Cen Li
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.